ArticleJournal of neuropathology and experimental neurology2009
Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome.
Article in Journal of neuropathology and experimental neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Molecular insights into prognostic model for meningiomas treated with stereotactic radiosurgery: negative impacts of 1q gain on tumor control and survival.Acta neuropathologica communications · 2025Observational
- The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care.Cancers · 2024Review
- DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines.Children (Basel, Switzerland) · 2024Article
- Molecular landscapes of longitudinal NF2/22q and non-NF2/22q meningiomas show different life histories.Brain pathology (Zurich, Switzerland) · 2023Article
- Review
- The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.Journal of neuro-oncology · 2022Review
- Meningiomas: An Overview of the Landscape of Copy Number Alterations in Samples from an Admixed Population.Journal of oncology · 2020Article
- Article
- Article
- A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.Neuro-oncology · 2016Article
- Article
- Tumor prognostic factors and the challenge of developing predictive factors.Current oncology reports · 2013Article
- A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer.American journal of human genetics · 2012Article
- Gain of chromosome arm 1q in atypical meningioma correlates with shorter progression-free survival.Neuropathology and applied neurobiology · 2012Article
- Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.Neuro-oncology · 2012Article
- Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.PloS one · 2012Article
- Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas.Acta neuropathologica · 2011Article
- Pathological classification and molecular genetics of meningiomas.Journal of neuro-oncology · 2010Review
- A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.Cancer research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Atypical meningiomas exhibit heterogeneous clinical outcomes. It is unclear which atypical meningiomas require aggressive multimodality treatment with surgery and radiation therapy versus surgery alone to prevent recurrence. Detailed molecular-genetic characterization of these neoplasms is necessary to understand their pathogenesis and identify clinically relevant genetic markers. Oligonucleotide array comparative genomic hybridization was used to identify frequent genetic alterations in 47 primary atypical meningiomas resected at Massachusetts General Hospital between August 1987 and September 2006. Eighty-five percent of samples exhibited loss of 22q, including the neurofibromatosis type 2 gene. The second most frequent regions of loss were confined to the short arm of chromosome 1, particularly 1p33-p36.2 (70%) and 1p13.2 (64%). Other frequent regions of loss, detected in more than 50% of samples, included 14q, 10q, 8q, 7p, 21q, 19, 9q34, and 4p16. Frequent regions of gain were detected along 1q (59%), 17q (44%), 9q34 (30%), and 7q36 (26%). Univariate marker-by-marker analysis of all frequently identified copy number alterations showed potential correlation between gain of 1q and shorter progression-free survival. Given the heterogeneous treatment outcomes of atypical meningioma, investigation of large-scale and focal genomic alterations in multi-institutional efforts may help clarify molecular-genetic signatures of clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.